eHEALTH Bureau Lilly, a research based organisation of pharmaceutical products, honoured for contribution to Millennium Development Goals (MDG) by the International Chamber of Commerce, United Nations Development Program and International Business Leaders Forum.An eminent international panel of judges has selected the company to receive a World Business and Development Award for demonstrating what can be achieved through successful partnerships in research on multidrug-resistant tuberculosis (MDR-TB). Lilly was chosen because the activities of The Lilly MDR-TB Partnership demonstrate a clear linkage between vital business practices and a contribution toward achieving MDG. The MDGs, endorsed by 189 countries, include eight goals that promote the reduction of poverty, better education, improved maternal health, gender equality, the lessening of child mortality and the eradication of infectious diseases, including tuberculosis. “We are extremely honoured and grateful, we believe that over time we can make a tangible difference in stamping out a disease that takes so many millions of lives,” said Jacques Tapiero, President, emerging markets for Lilly. Overtime, the partnership has produced real accomplishments despite significant obstacles and continues to build on lessons learned in achieving even more. Among Lilly’s efforts has been the transfer of drug-making technology and expertise to companies in China, India, Russia, South Africa and elsewhere. Working in over 80 nations and with more than 20 partners, The Lilly MDR-TB Partnership has trained doctors and nurses to recognise, treat, monitor and prevent the spread of multidrug-resistant tuberculosis.